A month after the FDA accepted its new drug application (NDA) for lead compound lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in patients with homozygous familial hypercholesteremia (HoFH) and familial chylomicronemia (FC), Aegerion Pharmaceuticals Inc. priced an underwritten public offering of 3.4 million shares of common stock at $14.75 each, seeking to raise approximately $47.3 million.